Viatris Pre-Tax Profit Margin 2010-2024 | VTRS
Current and historical pre-tax profit margin for Viatris (VTRS) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Viatris pre-tax profit margin for the three months ending September 30, 2024 was .
| Viatris Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$15.05B |
$-0.95B |
-6.32% |
| 2024-06-30 |
$15.24B |
$-0.64B |
-4.20% |
| 2024-03-31 |
$15.36B |
$0.09B |
0.55% |
| 2023-12-31 |
$15.43B |
$0.20B |
1.32% |
| 2023-09-30 |
$15.47B |
$2.53B |
16.34% |
| 2023-06-30 |
$15.60B |
$2.55B |
16.36% |
| 2023-03-31 |
$15.80B |
$2.61B |
16.51% |
| 2022-12-31 |
$16.26B |
$2.81B |
17.30% |
| 2022-09-30 |
$16.73B |
$1.14B |
6.82% |
| 2022-06-30 |
$17.19B |
$0.91B |
5.31% |
| 2022-03-31 |
$17.65B |
$0.31B |
1.73% |
| 2021-12-31 |
$17.89B |
$-0.66B |
-3.71% |
| 2021-09-30 |
$17.17B |
$-1.47B |
-8.59% |
| 2021-06-30 |
$15.60B |
$-1.43B |
-9.18% |
| 2021-03-31 |
$13.76B |
$-1.19B |
-8.67% |
| 2020-12-31 |
$11.95B |
$-0.72B |
-6.04% |
| 2020-09-30 |
$11.51B |
$0.43B |
3.72% |
| 2020-06-30 |
$11.50B |
$0.37B |
3.23% |
| 2020-03-31 |
$11.63B |
$0.30B |
2.58% |
| 2019-12-31 |
$11.50B |
$0.15B |
1.34% |
| 2019-09-30 |
$11.39B |
$0.10B |
0.84% |
| 2019-06-30 |
$11.29B |
$0.10B |
0.90% |
| 2019-03-31 |
$11.25B |
$0.17B |
1.54% |
| 2018-12-31 |
$11.43B |
$0.30B |
2.62% |
| 2018-09-30 |
$11.59B |
$0.55B |
4.74% |
| 2018-06-30 |
$11.72B |
$0.54B |
4.58% |
| 2018-03-31 |
$11.87B |
$0.84B |
7.10% |
| 2017-12-31 |
$11.91B |
$0.90B |
7.59% |
| 2017-09-30 |
$11.94B |
$0.80B |
6.72% |
| 2017-06-30 |
$12.01B |
$0.30B |
2.47% |
| 2017-03-31 |
$11.61B |
$0.18B |
1.51% |
| 2016-12-31 |
$11.08B |
$0.12B |
1.10% |
| 2016-09-30 |
$10.30B |
$0.12B |
1.12% |
| 2016-06-30 |
$9.94B |
$0.90B |
9.01% |
| 2016-03-31 |
$9.75B |
$0.87B |
8.95% |
| 2015-12-31 |
$9.43B |
$0.92B |
9.70% |
| 2015-09-30 |
$9.02B |
$0.97B |
10.74% |
| 2015-06-30 |
$8.41B |
$0.93B |
11.02% |
| 2015-03-31 |
$7.88B |
$0.88B |
11.22% |
| 2014-12-31 |
$7.72B |
$0.98B |
12.63% |
| 2014-09-30 |
$7.45B |
$0.90B |
12.03% |
| 2014-06-30 |
$7.13B |
$0.68B |
9.51% |
| 2014-03-31 |
$6.99B |
$0.76B |
10.87% |
| 2013-12-31 |
$6.91B |
$0.75B |
10.81% |
| 2013-09-30 |
$6.82B |
$0.75B |
10.92% |
| 2013-06-30 |
$6.86B |
$0.82B |
11.88% |
| 2013-03-31 |
$6.85B |
$0.79B |
11.47% |
| 2012-12-31 |
$6.80B |
$0.80B |
11.83% |
| 2012-09-30 |
$6.61B |
$0.74B |
11.23% |
| 2012-06-30 |
$6.38B |
$0.67B |
10.49% |
| 2012-03-31 |
$6.27B |
$0.68B |
10.89% |
| 2011-12-31 |
$6.13B |
$0.66B |
10.69% |
| 2011-09-30 |
$6.03B |
$0.52B |
8.69% |
| 2011-06-30 |
$5.81B |
$0.46B |
7.98% |
| 2011-03-31 |
$5.61B |
$0.36B |
6.46% |
| 2010-12-31 |
$5.45B |
$0.36B |
6.55% |
| 2010-09-30 |
$5.37B |
$0.33B |
6.20% |
| 2010-06-30 |
$5.28B |
$0.19B |
3.51% |
| 2010-03-31 |
$5.18B |
$0.21B |
3.98% |
| 2009-12-31 |
$5.09B |
$0.23B |
4.46% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$15.576B |
$15.427B |
|
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
|
